This chemical is primarily used in the field of targeted protein degradation, specifically for research and development of PROTACs (Proteolysis Targeting Chimeras). It is designed to selectively degrade CDK9, a cyclin-dependent kinase involved in regulating transcription and cell cycle progression. By facilitating the ubiquitination and subsequent proteasomal degradation of CDK9, it helps in studying the role of this kinase in diseases such as cancer, where CDK9 overexpression is often observed. Its application is crucial in developing novel therapeutic strategies to inhibit aberrant CDK9 activity, potentially leading to treatments for cancers and other CDK9-related disorders.